SG11201505599YA - Novel traps in the treatment of macular degeneration - Google Patents

Novel traps in the treatment of macular degeneration

Info

Publication number
SG11201505599YA
SG11201505599YA SG11201505599YA SG11201505599YA SG11201505599YA SG 11201505599Y A SG11201505599Y A SG 11201505599YA SG 11201505599Y A SG11201505599Y A SG 11201505599YA SG 11201505599Y A SG11201505599Y A SG 11201505599YA SG 11201505599Y A SG11201505599Y A SG 11201505599YA
Authority
SG
Singapore
Prior art keywords
treatment
macular degeneration
traps
novel
novel traps
Prior art date
Application number
SG11201505599YA
Inventor
John Clifford Chabala
Thomas A Jordan
Ke-Qing Ling
John G Gleason
William A Kinney
Original Assignee
Aldeyra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeyra Therapeutics Inc filed Critical Aldeyra Therapeutics Inc
Publication of SG11201505599YA publication Critical patent/SG11201505599YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
SG11201505599YA 2013-01-25 2014-01-21 Novel traps in the treatment of macular degeneration SG11201505599YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361756778P 2013-01-25 2013-01-25
PCT/US2014/012356 WO2014116593A1 (en) 2013-01-25 2014-01-21 Novel traps in the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
SG11201505599YA true SG11201505599YA (en) 2015-08-28

Family

ID=51227964

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505599YA SG11201505599YA (en) 2013-01-25 2014-01-21 Novel traps in the treatment of macular degeneration

Country Status (13)

Country Link
US (2) US10111862B2 (en)
EP (1) EP2948436A4 (en)
JP (1) JP6266023B2 (en)
KR (1) KR20150120380A (en)
CN (1) CN105228989A (en)
AU (1) AU2014209585A1 (en)
CA (1) CA2898869A1 (en)
HK (1) HK1217490A1 (en)
IL (1) IL239736A0 (en)
MX (1) MX2015009444A (en)
RU (1) RU2015126015A (en)
SG (1) SG11201505599YA (en)
WO (1) WO2014116593A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127945A1 (en) 2005-05-26 2006-11-30 Neuron Systems Compositions and methods of treating retinal disease
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CA2896032A1 (en) 2012-12-20 2014-06-26 Aldeyra Therapeutics, Inc. Peri-carbinols
MX2015009383A (en) 2013-01-23 2016-03-17 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment.
JPWO2016021706A1 (en) * 2014-08-08 2017-05-25 カズマパートナーズ株式会社 Fused heterocyclic compounds
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
JP7450242B2 (en) 2016-02-28 2024-03-15 アルデイラ セラピューティクス， インコーポレイテッド Treatment of allergic eye conditions with cyclodextrins
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CN110431130A (en) 2017-03-16 2019-11-08 奥尔德拉医疗公司 Multi-crystalline compounds and its purposes
CA3077362A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2021136244A1 (en) * 2019-12-30 2021-07-08 中国医药研究开发中心有限公司 Tricyclic compound, and preparation method therefor and medical use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (en) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Derivatives of 2-carbethoxy-3-aminoindole having antiinflammatory effect and process for preparing same
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
US5742954A (en) 1996-11-22 1998-04-28 Softub, Inc. Electrically powered spa jet unit
DE59813690D1 (en) 1997-05-02 2006-09-28 Schering Ag SUBSTITUTED HETEROCYCLES AND THEIR USE IN MEDICINAL PRODUCTS
JP2004500308A (en) 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ Modulator of protein tyrosine phosphatase
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
WO2001041757A1 (en) 1999-12-10 2001-06-14 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
FR2827599A1 (en) 2001-07-20 2003-01-24 Neuro3D Treating central nervous system disorders, e.g. anxiety, depression, schizophrenia or pain, using new or known 2-substituted quinoline or quinoxaline derivatives having xanthenuric acid modulating action
UA83620C2 (en) 2001-12-05 2008-08-11 Уайт Substituted benzoxazoles and analogues as estrogenic agents
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP2324823A3 (en) 2003-03-14 2011-11-16 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
EP2311465A1 (en) 2003-04-18 2011-04-20 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
KR101163800B1 (en) 2003-10-15 2012-07-09 산텐 세이야꾸 가부시키가이샤 Novel indazole derivative
CA2546042A1 (en) 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
KR20060135819A (en) 2004-02-17 2006-12-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Management of ophthalmologic disorders, including macular degeneration
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
WO2006049968A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2006127945A1 (en) * 2005-05-26 2006-11-30 Neuron Systems Compositions and methods of treating retinal disease
BRPI0710737A2 (en) 2006-04-14 2011-05-10 Prana Biotechnology Ltd use of compounds pb-10 33 useful for the treatment of age-related macular degeneration (amd) as well as said compounds
EP2079699A1 (en) 2006-07-25 2009-07-22 Envivo Pharmaceuticals, Inc. Quinoline derivatives
US7982071B2 (en) 2007-10-05 2011-07-19 Acucela Inc. Alkoxy compounds for disease treatment
CA2733966A1 (en) * 2008-08-12 2010-02-18 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
EP2477594A4 (en) 2009-07-15 2013-03-13 Univ Vanderbilt Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
WO2011072141A1 (en) * 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
AU2012205486B2 (en) 2011-01-12 2017-02-02 Array Biopharma, Inc. Substituted benzoazepines as toll-like receptor modulators
CN103442735B (en) 2011-01-31 2016-11-09 特米拉公司 Active principle for undesirable medical condition in mitigation technique field
CA2896032A1 (en) 2012-12-20 2014-06-26 Aldeyra Therapeutics, Inc. Peri-carbinols
MX2015009383A (en) 2013-01-23 2016-03-17 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment.

Also Published As

Publication number Publication date
AU2014209585A1 (en) 2015-07-23
WO2014116593A1 (en) 2014-07-31
CN105228989A (en) 2016-01-06
EP2948436A1 (en) 2015-12-02
HK1217490A1 (en) 2017-01-13
US20150344447A1 (en) 2015-12-03
JP6266023B2 (en) 2018-01-24
CA2898869A1 (en) 2014-07-31
RU2015126015A (en) 2017-03-03
US20190125729A1 (en) 2019-05-02
US10111862B2 (en) 2018-10-30
EP2948436A4 (en) 2016-07-13
MX2015009444A (en) 2016-04-15
IL239736A0 (en) 2015-08-31
KR20150120380A (en) 2015-10-27
JP2016505637A (en) 2016-02-25

Similar Documents

Publication Publication Date Title
HK1217490A1 (en) Novel traps in the treatment of macular degeneration
HK1218656A1 (en) Age-related macular degeneration treatment
HK1225654A1 (en) Compositions and methods for the treatment of presbyopia
HK1217439A1 (en) Toxic aldehyde related diseases and treatment
HK1222994A1 (en) Tobacco treatment
ZA201505390B (en) Compositions and methods for treating pests
PL3466425T3 (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
HK1215164A1 (en) Treatment methods
GB201308244D0 (en) Soil treatment
GB201304872D0 (en) Treatment
SG10201708547YA (en) Compositions and methods for treating and preventing macular degeneration
HK1214093A1 (en) Tobacco treatment
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
EP2968452A4 (en) Compositions and methods for treating retinal disease
HK1216391A1 (en) Combination treatment
GB201307310D0 (en) Treatment
GB2514124B (en) Turf Treatment
GB201321115D0 (en) Treatment
GB201309238D0 (en) Treatment
GB201306413D0 (en) The local treatment of ophthalmic diseases
GB201320653D0 (en) Treatment of plants
GB201316502D0 (en) Epithelial treatment
GB201308539D0 (en) Liquid treatment